Skip to content
Navigate to homepage - Cerba Research
Resource Library

Created:

E-book – CAR+T Drug Development
The Critical Role of Flow Cytometry

Being one of the leading technologies for cellular analysis, flow cytometry generates simultaneous high-throughput enumeration and individual cell characterization data. With the breakthrough of cellular immune therapies, such as CAR+ T, flow cytometry became a critical platform, not only for clinical laboratories, but also for drug developers and manufacturers.

Flow cytometry plays a crucial role in the production process of CAR+ T cells, where it is used for assessing transduction efficiency, purity, and characterization of the CAR+ T product before infusion. After manufacturing, when CAR+ T cells are infused into the patients, flow cytometry is used again in clinical laboratories to assess CAR+ T expansion, efficiency, and persistence and to monitor minimal residual disease (MRD).

In this e-book, Ans De Beuckelaer, Regional Head Flow Cytometry EU and Rowan Claeys, Clinical Biologist at Cerba Research, dive deeper into key elements of flow cytometry:

  • The importance of flow cytometry in Car+T clinical research and its uses
  • Key aspects in developing a CAR+ T trial
  • The added value of flow cytometryin multiple myeloma, Minimal Residual Disease (MRD) assessments and multiple Myeloma phenotype
  • Car+T-cell Therapy: patient treatment, targeted antigens and solutions for MRD assessments and multiple myeloma phenotype assessment.
Cerba Research - Ebook - CAR+T Drug Development The Critical Role of Flow Cytometry

Download your e-book here

Ebook – CAR+T Drug Development The Critical Role of Flow Cytometry
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform your research in the field of flow cytometry or CAR T

Contact Us
Resource Library

Created:

Automatization of Immunohistochemistry Data Analysis for Protocol Validation

This presentation was given by Marie Gerus-Durand, Principal Scientist & Validation Engineer at Cerba Research Montpellier at the JMP Discovery Summit Europe.

Cerba Research is a global company providing high-quality, specialized analytical and diagnostic solutions for clinical trials. Cerba Research Montpellier develops customized immunohistochemistry protocols to detect the expression of selected targets on patients’ tissue sections.

To be used in clinical trials, these protocols must meet the regulatory agencies’ criteria to ensure that the protocol will allow consistent results on precious patients’ samples. With the diversity of parameters evaluated and the types of evaluation possible in implementing these custom protocols, automating data analysis became a need.

Thanks to various JMP® tools, we have developed an automated analysis that saves time and homogenizes protocol performance reports by including statistical and graphical data in a Dashboard. This process, submitted as JMP Add-in, has been incorporated into our user workflows, thus facilitating our procedures.

Watch the full presentation here

Tour our IHC Centre of Excellence in 360°

Cerba Research - Montpellier IHC Lab Tour

Reach out to our experts and discover how we can help you transform your research and advance health

Contact Us
Resource Library

Created:

The Added Value of Flow Cytometry in CAR T-Cell Clinical Trials Webinar

Watch Cerba Research’s latest webinar, ‘The Added Value of Flow Cytometry in CAR T-Cell Clinical Trials’.

The Added Value of Flow Cytometry in CAR T Cell Clinical Trials

Cerba US Expansion Tour VF.00_04_27_19.Still010
Contact Us
Resource Library

Created:

A Single Picture Does Not Say It All: A Case for Comprehensive Biomarker Use in Cancer Research

During the Virtual Biomarkers Congress Eitan Akirav presented A Single Picture Does Not Say It All, a case for comprehensive biomarker use within oncology research. Did you miss out on his presentation during the conference? Now you can submit the form below to watch it at your own leisure!

Resource Library

Created:

Webinar: Turning Precision Medicine into Action in Immuno-Oncology

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

  • Jérôme Sallette, PhD, CSO Cerba Research
  • Shu Jen Chen, PhD, CSO ACT Genomics
  • Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
  • George Wei, PhD, Vice President R&D ACT Genomics
  • Renaud Burrer, PhD, Head of Histopathology Cerba Research
  • Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research

Resource Library

Created:

Analyzing Multiple Biomarkers with IHC: putting a 6-plex kit to the challenge

On November 16, 2021 Cerba Research and Akoya Biosciences held a webinar on how to analyze multiple biomarkers using Immunohistochemistry (IHC). The session was a deep dive in the Tissue Microenvironment (TME) with multiplex IF (Opal™) technology, discovering how to visualize, analyze, and quantify multiple phenotypes in situ.

As part of a long-standing collaboration with Akoya Biosciences, we agreed to test our pre-validated 6-plex panel kits, including one suitable for carcinoma immune-contexture investigations (CD8, CD68, FoxP3, PD1, PD-L1, PanCK). We were also able to put into practice Akoya’s pre-set imaging protocol on the Vectra® Polaris™ and related data analysis algorithm with inForm® software.

Speakers

  • Ivan Masetto, PhD, Field Application Scientist South of Europe at Akoya Biosciences
  • Maroua Tliba, Image Analyst at Cerba Research

Watch now

Resource Library

Created:

Metabolomic Characterization Of Very Early Hepatocellular Carcinoma In Cirrhotic Patients Submitted For Liver Transplantation

Publication – Metabolomic Characterization Of Very Early Hepatocellular Carcinoma In Cirrhotic Patients Submitted For Liver Transplantation

Click to download the publication
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us
Resource Library

Created:

Assessing Clinical Response in Multiple Myeloma Patients Treated with Monoclonal Antibodies

Poster – Assessing Clinical Response in Multiple Myeloma Patients Treated with Monoclonal Antibodies

Click here to download the poster
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Created:

HISTOSELECT: How to Overcome Challenges in Antibody Selection?

HISTOSELECT®: The number one solution for direct screening of large numbers of antibodies by immunohistochemistry (IHC).

HistoSelect

Click here to download the flyer
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your research

Contact Us